Page 144 - 南京医科大学学报自然科学版
P. 144
第43卷第9期
·1322 · 南 京 医 科 大 学 学 报 2023年9月
的影响,与常规 TDM 结合可能使初始剂量个体化, e28936
并有助于更快实现目标血药浓度。此外,群体药物 [11] WU C Y,LI G T,CHU C C,et al. Proactive therapeutic
代谢动力学整合了多种变量对药物暴露的影响,在 drug monitoring of vincristine in pediatric and adult can⁃
cer patients:current supporting evidence and future efforts
剂量个体化方面表现出巨大潜力,也是近年来TDM
[J]. Arch Toxicol,2023,97(2):377-392
研究的热点。TDM 结合药物遗传学和群体药物代
[12] ZIMMERMAN J J,KAHAN B D. Pharmacokinetics of si⁃
谢动力学对于探索SRL在VA中个体化精准用药方
rolimus in stable renal transplant patients after multiple
案具有重要意义,值得关注。 oral dose administration[J]. J Clin Pharmacol,1997,37
[参考文献] (5):405-415
[13] FILLER G,BENDRICK⁃PEART J,STROM T,et al. Char⁃
[1] HARBERS V E M,RONGEN G,VANDER VLEUTEN C
acterization of sirolimus metabolites in pediatric solid or⁃
J M,et al. Patients with congenital low⁃flow vascular mal⁃
gan transplant recipients[J]. Pediatr Transplant,2009,13
formation treated with low dose sirolimus[J]. Adv Ther,
(1):44-53
2021,38(6):3465-3482
[14] LEUNG L Y,LIM H K,ABELL M W,et al. Pharmacoki⁃
[2] TAN X,ZHANG J,ZHOU S,et al. Successful manage⁃
netics and metabolic disposition of sirolimus in healthy
ment of steroid⁃resistant vascular tumors associated with
male volunteers after a single oral dose[J]. Ther Drug
the Kasabach⁃Merritt phenomenon using sirolimus[J]. J
Monit,2006,28(1):51-61
Dermatol,2018,45(5):580-583
[15] U.S. FOOD AND DRUG ADMINISTRATION. Labels for
[3] OZEKI M,NOZAWA A,YASUE S,et al. The impact of
NDA 021110[EB/OL].(2022 ⁃ 02 ⁃ 11)[2022 ⁃ 10 ⁃ 24].
sirolimus therapy on lesion size,clinical symptoms,and
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
quality of life of patients with lymphatic anomalies[J].
event=overview.process&ApplNo=021110. Htm
Orphanet J Rare Dis,2019,14(1):141
[16] MACDONALD A,SCAROLA J,BURKE J T,et al. Clini⁃
[4] CHO Y J,KWON H,KWON Y J,et al. Effects of sirolimus
cal pharmacokinetics and therapeutic drug monitoring of
in the treatment of unresectable infantile hemangioma
sirolimus[J]. Clin Ther,2000,22(Suppl B):101-121
and vascular malformations in children:a single ⁃ center
[17] KAHAN B D,NAPOLI K L,KELLY P A,et al. Therapeu⁃
experience[J]. J Vasc Surg Venous Lymphat Disord,
tic drug monitoring of sirolimus:correlations with efficacy
2021,9(6):1488-1494
and toxicity[J]. Clin Transplant,2000,14(2):97-109
[5] STILLO F,MATTASSI R,DIOCIAIUTI A,et al. Guide⁃
[18] LIU J,FENG D,KAN X,et al. Polymorphisms in the
lines for vascular anomalies by the italian society for the CYP3A5 gene significantly affect the pharmacokinetics of
study of vascular anomalies(SISAV)[J]. Int Angiol, sirolimus after kidney transplantation[J]. Pharmacoge⁃
2022,41(2 Suppl 1):1-130 nomics,2021,22(14):903-912
[6] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血 [19] GAGO⁃SANCHEZ A I,FONT P,CARDENAS M,et al.
管瘤和脉管畸形的诊断及治疗指南(2019版)[J]. 组织 Real clinical impact of drug⁃drug interactions of immuno⁃
工程与重建外科杂志,2019,15(5):277-317 suppressants in transplant patients[J]. Pharmacol Res
[7] SABO A N,JANNIER S,BECKER G,et al. Sirolimus Perspect,2021,9(6):e00892
pharmacokinetics variability points to the relevance of [20] 徐晓琳,韩彤昕,成晓玲,等. 儿童应用西罗莫司血药浓
therapeutic drug monitoring in pediatric oncology[J]. 度波动2例原因分析[J]. 中国循证儿科杂志,2022,17
Pharmaceutics,2021,13(4):470 (3):235-239
[8] ALLEGAERT K. Developmental pharmacology ⁃ special [21] BABU M,PAVITHRAN K,Therapeutic drug monitoring
issues during childhood and adolescence[J]. Drug Res as a tool for therapy optimization[J/OL]. Drug Metab
(Stuttg),2018,68(S1):S10-S11 Lett,2022(2022⁃04⁃05)[2023⁃03⁃29]. DOI:10.2174/
[9] CHENG X,ZHAO Y,GU H,et al. The first study in pedi⁃ 1872312815666220405122021
atric:population pharmacokinetics of sirolimus and its ap⁃ [22] KRNAC D,REIFFOVA K,ROLINSKI B. A new HPLC⁃
plication in Chinese children with immune cytopenia[J]. MS/MS method for simultaneous determination of cyclo⁃
Int J Immunopathol Pharmacol,2020,34:2058738420934 sporine A,tacrolimus,sirolimus and everolimus for rou⁃
936 tine therapeutic drug monitoring[J]. J Chromatogr B Ana⁃
[10] ROSSLER J,BASELGA E,DAVILA V,et al. Severe ad⁃ lyt Technol Biomed Life Sci,2019,1128:121772
verse events during sirolimus“off⁃label”therapy for vascu⁃ [23] DINEIA P J,SANCHES A D,APARECIDA R F,et al. Si⁃
lar anomalies[J]. Pediatr Blood Cancer,2021,68(8): multaneous determination of everolimus,sirolimus,tacro⁃